DarioHealth stock received a Buy rating from BTIG on October 3, 2023, when the firm initiated coverage with a $6.00 price target. The available information does not establish whether that historical rating or target remains in effect.

DarioHealth stock rating and target

BTIG analyst David Larsen set the $6.00 target as part of the coverage initiation. A price target is an analyst’s estimate, not a guarantee that a stock will reach that price.

An accompanying market snapshot listed DarioHealth shares at $3.40, but did not specify when that price was observed. It should not be assumed to represent the share price on the rating date or the latest quotation.

Digital tools for chronic conditions

DarioHealth provides digital health programs for people managing chronic conditions, including diabetes and hypertension. Its services combine connected monitoring devices with mobile software and data analytics.

The available information does not provide a detailed explanation from BTIG for its rating or establish any subsequent change to the firm’s assessment.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.